<![CDATA[Chugai Pharmaceutical: News Releases]]> https://www.chugai-pharm.co.jp/english/index.html en-us Tue, 30 Jun 2026 15:30:00 +0900 <![CDATA[Launch of Joint Research Using Real-World Data and Generative AI (LLM) to Improve the Accuracy and Efficiency of Identifying Candidate Patients for Clinical Trials]]> https://www.chugai-pharm.co.jp/english/news/detail/20260630153000_1259.html Tue, 30 Jun 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260630153000_1259.html <![CDATA[Roche’s Announcement Regarding Enspryng (FDA Accepts Application for Thyroid Eye Disease)]]> https://www.chugai-pharm.co.jp/english/news/detail/20260630170000_1260.html Tue, 30 Jun 2026 17:00:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260630170000_1260.html <![CDATA[Avastin Receives Approval for Additional Indication as the World’s First Treatment for Neurofibromatosis Type 2]]> https://www.chugai-pharm.co.jp/english/news/detail/20260619153001_1255.html Fri, 19 Jun 2026 15:30:01 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260619153001_1255.html <![CDATA[Anti-CD20 Monoclonal Antibody Rituxan® Approved for Adult-onset Frequently Relapsing or Steroid-dependent Nephrotic Syndrome]]> https://www.chugai-pharm.co.jp/english/news/detail/20260619153000_1257.html Fri, 19 Jun 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260619153000_1257.html <![CDATA[Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy]]> https://www.chugai-pharm.co.jp/english/news/detail/20260619153002_1258.html Fri, 19 Jun 2026 15:30:02 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260619153002_1258.html <![CDATA[Tecentriq Filed for Additional Indication as Maintenance Therapy Following Definitive Chemoradiotherapy in Locally Advanced Esophageal Cancer]]> https://www.chugai-pharm.co.jp/english/news/detail/20260612153000_1256.html Fri, 12 Jun 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260612153000_1256.html